SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for Lifevantage (LFVN) — Mar 16, 2026

Lifevantage Corp
Date: March 16, 2026 · CIK: 0000849146 · Accession: 0000000000-26-002659

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-294183

Date
March 16, 2026
Author
Division of
Form
UPLOAD
Company
Lifevantage Corp

Letter

Re: LifeVantage Corporation Registration Statement on Form S-3 Filed March 10, 2026 File No. 333-294183 Dear Steven Fife:

March 16, 2026

Steven Fife Chief Executive Officer LifeVantage Corporation 3300 Triumph Blvd., Suite 700 Lehi, UT 84043

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Kirt W Shuldberg, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 16, 2026

Steven Fife
Chief Executive Officer
LifeVantage Corporation
3300 Triumph Blvd., Suite 700
Lehi, UT 84043

 Re: LifeVantage Corporation
 Registration Statement on Form S-3
 Filed March 10, 2026
 File No. 333-294183
Dear Steven Fife:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tyler Howes at 202-551-3370 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Kirt W Shuldberg, Esq.
</TEXT>
</DOCUMENT>